SLXN

Silexion Therapeutics Corp

Sağlık

NON-COMPLIANT — One or more ratios exceed the threshold; the company is not compliant with halal investment criteria.

$2.66

Price (1 Year)

Participation Finance Screening Ratios

Non-compliant debt / Total market cap %0 / %30

Non-compliant assets / Total market cap %0 / %30

Non-compliant revenue / Total income %100 / %5

Ratios are taken from an AAOIFI-based screening file; this does not constitute a religious ruling.

About the Company

Silexion Therapeutics Corp, a clinical-stage biotechnology company, discovers and develops RNA interference (RNAi) therapies for KRAS-driven cancers. Its products comprise SIL204 second-generation small interfering RNA (siRNA) undergoing phase 2/3 clinical evaluation for pancreatic cancer and silence mutant KRAS oncogene expression.

Website

Analysis (Turkish): SLXN Hissesi Caiz mi, Helal mi? Silexion Therapeutics Corp Katılım Analizi